Distinguished in Heart Failure

Junbo B. Ge

No. 180 Fenglin Road, 
Xuhui, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Heart Failure
No. 180 Fenglin Road, 
Xuhui, CN 
OverviewLocationsClinical Research

Overview

Junbo Ge practices in Xuhui, China. Ge is rated as a Distinguished expert by MediFind in the treatment of Heart Failure. Their top areas of expertise are Heart Attack, Cardiomyopathy, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Angioplasty.

Their clinical research consists of co-authoring 1006 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 121 articles in the study of Heart Failure.

Locations

No. 180 Fenglin Road, Xuhui, 200032, China
Other Locations
180 Fenglin Road, Shanghai, China
Fudan University. Shanghai Institute Of Cardiovascular Diseases. 180 Feng Lin Road, Shanghai, 200032, China
No. 91 Jiefang Road, Yantai, 264000, China
180 Fenglin Road, 200032, Zhongshan, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Pressure Microcatheter Vs Pressure Wire for Clinical Decision Making and PCI Optimization
Pressure Microcatheter Vs Pressure Wire for Clinical Decision Making and PCI Optimization
Enrollment Status: Recruiting
Publish Date: January 07, 2025
Intervention Type: Procedure
Study Phase: Phase 4
A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, OPC Trial
A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, OPC Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 25, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, RCT Trial
A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, RCT Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 25, 2024
Intervention Type: Device
Study Phase: Not Applicable
Pressure Microcatheter for Physiological Measurements - A Prospective, Multicenter, Randomized Study
Pressure Microcatheter for Physiological Measurements - A Prospective, Multicenter, Randomized Study
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Device
A Prospective, Multicenter, Single Blind, Randomized and Sham Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
A Prospective, Multicenter, Single Blind, Randomized and Sham Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease
A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Drugs: AK102, Statins, Ezetimibe
Study Phase: Phase 2
Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting in the Treatment of True Bifurcation Lesions: a Multicenter, Noninferior, Randomized, Controlled Trial (the DK Culotte-I Study)
Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting in the Treatment of True Bifurcation Lesions: a Multicenter, Noninferior, Randomized, Controlled Trial (the DK Culotte-I Study)
Enrollment Status: Completed
Publish Date: September 27, 2022
Intervention Type: Device
Study Phase: Not Applicable
Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for FFR Measurement: A Multi-center Prospective Control Study
Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for FFR Measurement: A Multi-center Prospective Control Study
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Device
Clinical Evaluation of A New High-speed and High-resolution Intravascular Ultrasound System: A Multi-center Prospective Control Study
Clinical Evaluation of A New High-speed and High-resolution Intravascular Ultrasound System: A Multi-center Prospective Control Study
Enrollment Status: Completed
Publish Date: May 11, 2022
Intervention Type: Device
Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.
Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.
Enrollment Status: Completed
Publish Date: May 26, 2020
Intervention Type: Device
An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003
An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003
Enrollment Status: Withdrawn
Publish Date: May 09, 2017
Intervention Type: Drug
Study Phase: Phase 4
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Withdrawn
Publish Date: May 09, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 11 Less Clinical Trials

1006 Total Publications

CCL21 Enhances Platelet Activation and Atherothrombosis via CCR7 Activation.
CCL21 Enhances Platelet Activation and Atherothrombosis via CCR7 Activation.
Journal: Circulation research
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ge's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 17 Advanced Conditions
View All 76 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile